PriceTargets.com logo

Aardvark Therapeutics - AARD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $19.70
  • Forecasted Upside: 429.57%
  • Number of Analysts: 13
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$3.72 As of 06/16/2026 05:00 PM ET
▼ -0.12 (-3.13%)

This chart shows the closing price for AARD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aardvark Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AARD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AARD

Analyst Price Target is $19.70
▲ +429.57% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Aardvark Therapeutics in the last 3 months. The average price target is $19.70, with a high forecast of $47.00 and a low forecast of $3.00. The average price target represents a 429.57% upside from the last price of $3.72.

This chart shows the closing price for AARD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in Aardvark Therapeutics. This rating has held steady since April 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
5/17/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
6/16/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/27/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
5/15/2026B. Riley FinancialLower TargetBuy ➝ Buy$8.00 ➝ $7.00
5/15/2026BTIG ResearchDowngradeBuy ➝ Hold
5/15/2026Morgan StanleyReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.00
5/13/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
4/29/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
3/27/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/24/2026BTIG ResearchReiterated RatingBuy ➝ Buy$9.00
3/2/2026Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$18.00 ➝ $6.00
3/2/2026OppenheimerLower TargetOutperform ➝ Outperform$35.00 ➝ $21.00
3/2/2026Stifel NicolausReiterated RatingBuy ➝ Hold$24.00 ➝ $6.00
3/2/2026Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$29.00 ➝ $7.00
3/2/2026HC WainwrightReiterated RatingBuy ➝ Neutral
3/2/2026BTIG ResearchLower TargetBuy ➝ Buy$26.00 ➝ $9.00
2/10/2026BTIG ResearchReiterated RatingBuy ➝ Buy$26.00
2/9/2026HC WainwrightReiterated RatingBuy ➝ Buy$40.00
1/28/2026B. Riley FinancialInitiated CoverageBuy$32.00
1/12/2026Raymond James FinancialReiterated RatingStrong-Buy ➝ Strong-Buy$47.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/23/2025OppenheimerInitiated CoverageOutperform$35.00
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/12/2025William BlairInitiated CoverageOutperform
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/2/2025Raymond James FinancialInitiated CoverageStrong-Buy$47.00
12/2/2025Raymond James FinancialInitiated CoverageStrong-Buy$47.00
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/14/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
11/14/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$19.00 ➝ $18.00
11/13/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/7/2025BTIG ResearchInitiated CoverageBuy$26.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/1/2025JonesTradingInitiated CoverageBuy$33.00
9/29/2025Stifel NicolausInitiated CoverageBuy$24.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/23/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00
8/28/2025Bank of AmericaLower TargetBuy ➝ Buy$26.00 ➝ $25.00
8/14/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$20.00 ➝ $19.00
6/30/2025HC WainwrightInitiated CoverageBuy$40.00
5/15/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/1/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.00
4/1/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00
3/27/2025Bank of AmericaBoost TargetBuy ➝ Buy$22.00 ➝ $26.00
3/10/2025Morgan StanleyInitiated CoverageOverweight$29.00
3/10/2025Bank of AmericaInitiated CoverageBuy$22.00
3/10/2025Royal Bank Of CanadaInitiated CoverageOutperform$21.00
3/10/2025Cantor FitzgeraldInitiated CoverageOverweight$50.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2025
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2026
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2026
  • 5 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2026
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/17/2026
  • 0 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/17/2026
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/16/2026

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Aardvark Therapeutics logo
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $3.72
Low: $3.72
High: $4.00

50 Day Range

MA: $4.67
Low: $3.48
High: $6.73

52 Week Range

Now: $3.72
Low: $3.35
High: $17.94

Volume

107,636 shs

Average Volume

139,540 shs

Market Capitalization

$81.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Aardvark Therapeutics?

The following equities research analysts have issued research reports on Aardvark Therapeutics in the last year: B. Riley Financial, Inc., Bank of America Corporation, BTIG Research, Cantor Fitzgerald, HC Wainwright, JonesTrading, Morgan Stanley, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Royal Bank Of Canada, Stifel Nicolaus, Weiss Ratings, and William Blair.
View the latest analyst ratings for AARD.

What is the current price target for Aardvark Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aardvark Therapeutics in the last year. Their average twelve-month price target is $19.70, suggesting a possible upside of 429.6%. Raymond James Financial, Inc. has the highest price target set, predicting AARD will reach $47.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for Aardvark Therapeutics in the next year.
View the latest price targets for AARD.

What is the current consensus analyst rating for Aardvark Therapeutics?

Aardvark Therapeutics currently has 2 sell ratings, 4 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AARD, but not buy more shares or sell existing shares.
View the latest ratings for AARD.

What other companies compete with Aardvark Therapeutics?

Other companies that are similar to Aardvark Therapeutics include Silence Therapeutics, Abeona Therapeutics, Amarin, Cellectis and Siga Technologies. Learn More about companies similar to Aardvark Therapeutics.

How do I contact Aardvark Therapeutics' investor relations team?

Aardvark Therapeutics' physical mailing address is 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122. The company's listed phone number is (858) 225-7696 and its investor relations email address is [email protected]. The official website for Aardvark Therapeutics is aardvarktherapeutics.com. Learn More about contacing Aardvark Therapeutics investor relations.